SCHEMBL2125605

SCHEMBL2125605

CC(O[C@H]1CCCC[C@@H]1N1CCC2(C1)OCCO2)c1cccc2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 3/20 0.39
▸ SCN5A Q14524 3/20 0.39
▸ HSD11B1 P28845 2/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ KMT2A Q03164 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ METAP2 P50579 1/20 0.32
▸ METAP1 P53582 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ SLC6A2 P23975 2/20 0.32
▸ SLC6A4 P31645 2/20 0.32
▸ SLC6A3 Q01959 2/20 0.32
▸ ALDH1A1 P00352 3/20 0.31
▸ GAA P10253 2/20 0.31
▸ HPGD P15428 2/20 0.31
▸ HSD17B10 Q99714 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2122586 1.00 KCNA5 (0.39) KCNA5SCN5AHSD11B1KDM4EKMT2A
SCHEMBL2124869 1.00 KCNA5 (0.39) KCNA5SCN5AHSD11B1KDM4EKMT2A
SCHEMBL1762462 0.76 KCNA5 (0.69) KCNA5SCN5AKDM4ESLC6A2SLC6A4
SCHEMBL2625038 0.76 KCNA5 (0.69) KCNA5SCN5AKDM4ESLC6A2SLC6A4
SCHEMBL1762344 0.76 KCNA5 (0.69) KCNA5SCN5AKDM4ESLC6A2SLC6A4
SCHEMBL12204055 0.76 KCNA5 (0.69) KCNA5SCN5AKDM4ESLC6A2SLC6A4
SCHEMBL1762200 0.76 KCNA5 (0.58) KCNA5SCN5AHSD11B1KMT2AMEN1
SCHEMBL1762342 0.76 KCNA5 (0.58) KCNA5SCN5AHSD11B1KMT2AMEN1
SCHEMBL3574304 0.76 KCNA5 (0.58) KCNA5SCN5AHSD11B1KMT2AMEN1
Hydrochloric Acid SCHEMBL1762465 0.75 KCNA5 (0.57) KCNA5SCN5AHSD11B1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095073-A1 ION CHANNEL MODULATING ACTIVITY II CARDIOME PHARMA CORP. (CA) 2012-04-19 — — US disclosed
US-7674820-B2 Ion channel modulating activity I CARDIOME PHARMA CORP. (CA) 2010-03-09 — — US disclosed
US-20090270478-A1 ION CHANNEL MODULATING ACTIVITY II CARDIOME PHARMA CORP. (CA) 2009-10-29 — — US disclosed
US-20060135536-A9 Ion channel modulating activity I CARDIOME PHARMA CORP. (CA) 2006-06-22 — — US disclosed
US-20050070552-A1 Ion channel modulating activity I CARDIOME PHARMA CORP. (CA) 2005-03-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070552-A1 Ion channel modulating activity I KCNN1, KCNN3, KCNH1 KCNA5 45/4885SCN5A 71/4885HSD11B1 3797/4885
US-20060135536-A9 Ion channel modulating activity I KCNN1, KCNN3, KCNH1 KCNA5 45/4885SCN5A 71/4885HSD11B1 3797/4885
US-20090270478-A1 ION CHANNEL MODULATING ACTIVITY II KCNH1, KCNN3, KCNN2 KCNA5 31/4885SCN5A 59/4885HSD11B1 3790/4885
US-20120095073-A1 ION CHANNEL MODULATING ACTIVITY II KCNH1, KCNN3, KCNJ2 KCNA5 34/4885SCN5A 64/4885HSD11B1 3927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback